Combined CD36‑targeted senolysis and NIK agonism prevents epigenetic fixation of T‑cell exhaustion in inflammaging

Hypothesis

Combined inhibition of CD36‑driven SASP production and pharmacologic activation of NF‑κB inducing kinase (NIK) will prevent the epigenetic transition from progenitor‑exhausted (Tpex: TCF‑1+CD39−) to terminally exhausted (Ttex: TCF‑1−CD39+) CD8⁺ T cells during inflammaging, thereby preserving cytokine‑producing capacity.

Rationale

Chronic low‑grade inflammation fuels a senescence‑associated secretory phenotype (SASP) that activates NF‑κB/NLRP3 in surrounding immune cells, driving T‑cell exhaustion via persistent IL‑6, IL‑1β and TNF‑α signaling 1. CD36 acts as an upstream sensor that links lipid‑induced stress to SASP transcription through NF‑κB 7. Simultaneously, NIK sustains non‑canonical NF‑κB signaling that preserves glycolytic flux and IFN‑γ production in exhausted CD8⁺ T cells 5. We propose that CD36‑mediated SASP elevates mitochondrial ROS, stabilizes HIF‑1α, and promotes TOX‑dependent chromatin remodeling that locks the Ttex state. NIK activation counteracts this by boosting NAD⁺ via NAMPT, reducing ROS and permitting TCF‑1 re‑expression. Thus, targeting both the SASP source (CD36) and the intracellular metabolic‑epigenetic rescue (NIK) should act synergistically to keep T cells in the reversible Tpex compartment.

Predictions

• In aged mice, CD36 blockade alone will lower SASP cytokines but will not significantly increase TCF‑1⁺CD8⁺ T cells.
• NIK agonism alone will improve IFN‑γ production yet fail to reduce CD39⁺Ttex accumulation because upstream inflammatory pressure remains.
• The combination will produce a greater than additive increase in the TCF‑1/CD39 ratio, decreased TOX and epigenetic silencing markers (e.g., H3K27me3 at the Tcf7 locus), and enhanced viral clearance or tumor control compared with either monotherapy.

Experimental Design

1. Animals: 20‑month‑old C57BL/6 mice (n=10 per group).
2. Treatments (4‑week course):
   • Vehicle control
   • CD36 antagonist (e.g., sulfosuccinimidyl oleate, SSO) 7
   • NIK activator (small‑molecule NIK agonist, e.g., NIK‑SMI1) 5
   • Combined CD36 antagonist + NIK activator
3. Readouts (pre‑ and post‑treatment):
   • Flow cytometry for CD8⁺ TCF‑1, CD39, TOX, PD‑1, TIM‑3.
   • Intracellular cytokine staining (IFN‑γ, TNF‑α) after ex vivo stimulation.
   • Plasma SASP cytokines (IL‑6, IL‑1β, TNF‑α) by ELISA.
   • Mitochondrial ROS (MitoSOX) and NAD⁺/NADH ratio in sorted CD8⁺ T cells.
   • ATAC‑seq and H3K27me3 ChIP‑seq on Tcf7 promoter to assess epigenetic state.
   • Functional assay: LCMV‑Armstrong chronic infection model or B16‑OVA tumor challenge to measure viral load/tumor growth.
4. Analysis: Two‑way ANOVA with post‑hoc Tukey; synergy evaluated via Bliss independence model.

Potential Outcomes and Interpretation

• Synergistic improvement (greater than additive) in TCF‑1⁺CD39⁻ frequency and functional cytokine production would support the hypothesis that upstream SASP clearance lowers the inflammatory threshold needed for NIK‑mediated metabolic‑epigenetic rescue to be effective.
• Additive or no effect would suggest that either SASP inhibition or NIK activation alone is sufficient, or that additional pathways (e.g., mTOR, AMPK) dominate the epigenetic fixation.
• Worsening (e.g., increased exhaustion) could indicate off‑target toxicity or that NIK activation in a high‑SASP milieu exacerbates NF‑κB‑driven inflammation, falsifying the proposed mechanism.

This design directly tests the reversibility window hypothesis in aging, provides mechanistic insight into ROS‑HIF‑1α‑TOX axis, and offers a translatable combinatorial strategy (senolytic + metabolic modulator) to revitalize T‑cell reserves before epigenetic fixation becomes irreversible.